HEALTH PROFESSIONAL · SOURCE READING

Selection of Therapy for Chronic Lymphocytic Leukemia

Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Treatment of patients with chronic lymphocytic leukemia (CLL) must be individualized based on the clinical behavior of the disease.[1] Because this disease is generally not curable, occurs in an older population, and often progresses slowly, it is most often treated in a conservative fashion.[2]

Source links and citations

In older trials with data collected from the 1970s through the 1990s, the median survival for all patients ranged from 8 to 12 years.[3,4] However, with the introduction of the B-cell receptor inhibitors and targeting of BCL2, the median survival for all patients has not been reached with over 10 years of follow-up.

Source links and citations

Treatment of patients with CLL ranges from observation with treatment of infectious, hemorrhagic, or immunological complications to a variety of therapeutic options administered as single agents or combination therapy. In asymptomatic patients, treatment may be deferred until the disease progresses and symptoms occur.[3] Because the rate of progression may vary from patient to patient, with long periods of stability and sometimes spontaneous regressions, frequent and careful observation is required to monitor the clinical course.[5] Although even asymptomatic patients with del(17p) on fluorescence in situ hybridization (FISH) analysis (or those with a TP53 pathogenic variant) may be followed with watchful waiting, frequent monitoring may be required to avert rapid progression. A meta-analysis of randomized trials showed no survival benefit for immediate versus delayed therapy for patients with early-stage disease.[6][Level of evidence A1] For patients with progressing CLL, treatment will not be curative in most cases. Selected patients treated with allogeneic stem cell transplant have achieved prolonged disease-free survival (DFS), sometimes exceeding 20 years.[7-11] Prolonged DFS was also noted in young patients (<60 years) with IGH hypermutation who received the FCR regimen (fludarabine, cyclophosphamide, and rituximab).[12-14]

Source links and citations

The following clinical factors may be helpful in predicting progression of disease:[2]

Source links and citations

IGH pathogenic variant.

Chromosomal abnormalities found by FISH or cytogenetic analysis.

Beta-2-microglobulin.

Lymphocyte doubling time.

The International Workshop on Chronic Lymphocytic Leukemia defines symptomatic or progressive CLL as having the following signs and symptoms:[15]

Source links and citations

Evidence of progressive marrow failure—the development or worsening of anemia and/or thrombocytopenia (in some patients, platelet counts <100 × 109/L may remain stable over a long period; this does not automatically require therapeutic intervention). Cutoff levels of hemoglobin less than 10 g/dL or platelet counts less than 50 × 109/L are generally regarded as an indication for treatment.

Massive (i.e., ≥6 cm below the left costal margin), progressive, or symptomatic splenomegaly.

Massive lymph nodes (i.e., ≥10 cm in longest diameter), progressive, or symptomatic lymphadenopathy.

Progressive lymphocytosis with an increase of 50% or more over a 2-month period, or lymphocyte-doubling time (LDT) less than 6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts less than 30 × 109/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (e.g., infections or steroid administration) should be excluded.

Autoimmune complications, including anemia or thrombocytopenia that respond poorly to corticosteroids.

Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, or spine). Disease-related symptoms defined as any of the following:

Unintentional weight loss of 10% or more within the previous 6 months.

Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, or spine). Disease-related symptoms defined as any of the following:

Significant fatigue (i.e., Eastern Cooperative Oncology Group performance scale 2 or worse, cannot work, or unable to perform usual activities).

Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, or spine). Disease-related symptoms defined as any of the following:

Fevers of 100.5°F or 38.0°C or higher for 2 or more weeks without evidence of infection.

Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, or spine). Disease-related symptoms defined as any of the following:

Night sweats for at least 1 month without evidence of infection.

Continue within this section

Considerations for the Selection of Therapy →Adverse Sequelae of the Disease and Therapy →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice